Valuation: CSL Limited

Market Cap 61.93B 55.28B 51.38B 46.73B 87.92B 5,866B 89.51B 617B 241B 3,060B 232B 227B 9,793B P/E 2027 *
21.3x
P/E 2028 * 19.4x
Enterprise Value 71.16B 63.52B 59.04B 53.7B 101B 6,740B 103B 709B 277B 3,517B 267B 261B 11,253B EV / Sales 2027 *
4.52x
EV / Sales 2028 * 4.34x
Free-Float
99.97%
Yield 2027 *
2.32%
Yield 2028 * 2.46%
1 day+1.25%
1 week+2.70%
Current month+1.45%
1 month+8.94%
3 months+52.00%
6 months+35.36%
Current year+8.25%
1 week 180.5
Extreme 180.5
186.9
1 month 172.7
Extreme 172.7
187
Current year 90
Extreme 90
187
1 year 90
Extreme 90
222.47
3 years 90
Extreme 90
313.55
5 years 90
Extreme 90
319.78
10 years 90
Extreme 90
342.75
Manager TitleAgeSince
Chief Executive Officer 63 2026-02-10
Director of Finance/CFO 52 2025-10-06
Chief Operating Officer - 2025-04-30
Director TitleAgeSince
Director/Board Member 72 2018-10-16
Director/Board Member 70 2011-02-01
Director/Board Member 71 2019-12-08
Date Insider Type Main position Quantity % Market Cap. Importance
8/26/26 Free

Director

523 0.0001%
8/26/26 Free 317 0.0001% -
8/26/26 Free

Director

1,586 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
+1.25%+2.70%-11.42%-22.57% 61.54B
+3.55%+7.01%+51.42%+102.97% 1,077B
-0.25%-1.25%+32.49%+60.78% 612B
+0.59%+4.03%+25.28%+92.49% 501B
-1.48%+1.97%+72.62%+39.42% 364B
+2.37%+5.47%+32.67%+48.87% 353B
+2.64%+4.90%+21.01%+43.85% 278B
+3.24%+4.25%-0.31%+15.71% 251B
+1.86%+6.53%+45.98%+51.29% 230B
+2.49%+6.98%+33.03%+98.70% 190B
Average +1.71%+1.91%+30.28%+53.15% 391.81B
Weighted average by Cap. +1.87%+1.58%+37.73%+69.27%

Financials

2027 *2028 *
Net sales 15.76B 14.06B 13.07B 11.89B 22.37B 1,492B 22.77B 157B 61.44B 779B 59.13B 57.88B 2,492B 16.32B 14.56B 13.54B 12.31B 23.16B 1,545B 23.58B 163B 63.62B 806B 61.23B 59.93B 2,580B
Net income 2.82B 2.52B 2.34B 2.13B 4.01B 267B 4.08B 28.12B 11B 139B 10.59B 10.36B 446B 3.15B 2.81B 2.61B 2.38B 4.47B 298B 4.55B 31.38B 12.28B 156B 11.82B 11.57B 498B
Net Debt 9.23B 8.24B 7.66B 6.97B 13.11B 874B 13.34B 92B 36B 456B 34.65B 33.91B 1,460B 8.92B 7.96B 7.4B 6.73B 12.66B 845B 12.89B 88.88B 34.78B 441B 33.47B 32.76B 1,410B
Projected Income Statement - Annual - CSL Limited
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,000
Date Price Change Volume
26-10-15 A$186.90 +1.25% 1,373,510
26-10-14 A$184.59 +0.01% 913,036
26-10-13 A$184.58 -0.12% 635,952
26-10-12 A$184.81 +0.53% 595,580
26-10-09 A$183.84 +1.31% 1,038,865
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - CSL Limited
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
129.32USD
Average target price
129.04USD
Spread / Average Target
-0.21%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - CSL Limited